Sort   by:  
 Page size 
UnknownBevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial.
Not available
S-EPMC3732014 | biostudies-literature
UnknownOxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses.
Not available
S-EPMC3188282 | biostudies-literature
UnknownValidation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.
Not available
S-EPMC3871512 | biostudies-literature
UnknownPrognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14.
Not available
S-EPMC4981975 | biostudies-literature
UnknownRisk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.
Not available
S-EPMC3221521 | biostudies-literature
UnknownPredictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.
Not available
S-EPMC3488269 | biostudies-literature
UnknownAdjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
Not available
S-EPMC3341142 | biostudies-literature
UnknownIntrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.
Not available
S-EPMC4397278 | biostudies-literature
UnknownPrimary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10.
Not available
S-EPMC3434981 | biostudies-literature
UnknownFour-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
Not available
S-EPMC3164242 | biostudies-literature
Sort   by:  
 Page size